BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

540 related articles for article (PubMed ID: 25899660)

  • 1. Haemolytic disease of the fetus and newborn.
    de Haas M; Thurik FF; Koelewijn JM; van der Schoot CE
    Vox Sang; 2015 Aug; 109(2):99-113. PubMed ID: 25899660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Haemolytic disease of the fetus and newborn/HDFN/timing in pregnant women and prophylaxis].
    Kulinska R
    Akush Ginekol (Sofiia); 2014; 53(2):58-63. PubMed ID: 25098112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of screening for red cell antibodies, other than anti-D, to detect hemolytic disease of the fetus and newborn: a population study in the Netherlands.
    Koelewijn JM; Vrijkotte TG; van der Schoot CE; Bonsel GJ; de Haas M
    Transfusion; 2008 May; 48(5):941-52. PubMed ID: 18248570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Third trimester screening for alloimmunisation in Rhc-negative pregnant women: evaluation of the Dutch national screening programme.
    Slootweg YM; Koelewijn JM; van Kamp IL; van der Bom JG; Oepkes D; de Haas M
    BJOG; 2016 May; 123(6):955-63. PubMed ID: 26661943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of red cell alloimmunisation in pregnancy: the non-invasive monitoring of the disease.
    Illanes S; Soothill P
    Prenat Diagn; 2010 Jul; 30(7):668-73. PubMed ID: 20572110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe anti-D haemolytic disease of fetal and newborn in rhesus D negative primigravida.
    Hassan MZ; Iberahim S; Abdul Rahman WSW; Zulkafli Z; Bahar R; Ramli M; Mohd Noor NH; Mustaffa R
    Malays J Pathol; 2019 Apr; 41(1):55-58. PubMed ID: 31025639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Red Blood Cell Alloimmunization in the Pregnant Patient.
    Webb J; Delaney M
    Transfus Med Rev; 2018 Oct; 32(4):213-219. PubMed ID: 30097223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neonatal and Obstetrical Outcomes of Pregnancies Complicated by Alloimmunization.
    Bahr TM; Tweddell SM; Zalla JM; Dizon-Townson D; Ohls RK; Henry E; Ilstrup SJ; Kelley WE; Ling CY; Lindgren PC; O'Brien EA; Christensen RD
    Pediatrics; 2024 Jun; 153(6):. PubMed ID: 38784990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antigen specificity determines anti-red blood cell IgG-Fc alloantibody glycosylation and thereby severity of haemolytic disease of the fetus and newborn.
    Sonneveld ME; Koelewijn J; de Haas M; Admiraal J; Plomp R; Koeleman CA; Hipgrave Ederveen AL; Ligthart P; Wuhrer M; van der Schoot CE; Vidarsson G
    Br J Haematol; 2017 Feb; 176(4):651-660. PubMed ID: 27891581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of maternal alloimmunization in Southern Pakistan - a study in a cohort of 1000 pregnant women.
    Karim F; Moiz B; Kamran N
    Transfus Apher Sci; 2015 Feb; 52(1):99-102. PubMed ID: 25532481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on HDFN: new information on long-standing controversies.
    Eder AF
    Immunohematology; 2006; 22(4):188-95. PubMed ID: 17430078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maternal red blood cell alloimmunisation in south western Uganda.
    Natukunda B; Mugyenyi G; Brand A; Schonewille H
    Transfus Med; 2011 Aug; 21(4):262-6. PubMed ID: 21371143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-invasive prenatal testing for management of haemolytic disease of the fetus and newborn induced by maternal alloimmunisation.
    Hyland CA; O'Brien H; Flower RL; Gardener GJ
    Transfus Apher Sci; 2020 Oct; 59(5):102947. PubMed ID: 33115620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. History and current standard of postnatal management in hemolytic disease of the fetus and newborn.
    De Winter DP; Hulzebos C; Van 't Oever RM; De Haas M; Verweij EJ; Lopriore E
    Eur J Pediatr; 2023 Feb; 182(2):489-500. PubMed ID: 36469119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Management of feto-maternal red cell allo-immunizations].
    Bricca P; Guinchard E; Guitton Bliem C
    Transfus Clin Biol; 2011 Apr; 18(2):269-76. PubMed ID: 21397546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of non-invasive prenatal testing (NIPT) for fetal blood group typing in Australia.
    Ginige S; Daly J; Hyland C; Powley T; O'Brien H; Moreno AM; Gardener G; Flower R
    Aust N Z J Obstet Gynaecol; 2022 Feb; 62(1):33-36. PubMed ID: 34661280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The risk assessment study for hemolytic disease of the fetus and newborn in a University Hospital in Turkey.
    Altuntas N; Yenicesu I; Himmetoglu O; Kulali F; Kazanci E; Unal S; Aktas S; Hirfanoglu I; Onal E; Turkyilmaz C; Ergenekon E; Koc E; Atalay Y
    Transfus Apher Sci; 2013 Jun; 48(3):377-80. PubMed ID: 23619329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemolytic disease of the fetus and newborn in the molecular era.
    Fasano RM
    Semin Fetal Neonatal Med; 2016 Feb; 21(1):28-34. PubMed ID: 26589360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of alloantibodies associated with haemolytic disease of the fetus and newborn in pregnant women at the Ekiti State University Teaching Hospital, Ado-Ekiti, Southwest Nigeria.
    Olayanju AO; Chris NI; Emmanuel AE; Oyetunde AB; Adebisi KY; Okolo CS
    Afr J Reprod Health; 2023 Jun; 27(6s):70-78. PubMed ID: 37694704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protection against Rh D-haemolytic disease of the newborn by a diminished transport of maternal IgG to the fetus.
    Dooren MC; Engelfriet CP
    Vox Sang; 1993; 65(1):59-61. PubMed ID: 8362516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.